Evidence map›Paper›PMID 24574804›Full record

ArticleWorld journal of gastroenterology2014

Bax protein may influence the invasion of colorectal cancer.

Anna Pryczynicz, Mariusz Gryko, Katarzyna Niewiarowska, Dariusz Cepowicz, Marek Ustymowicz, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. HANSynergy: Heterogeneous Graph Attention Network for Drug Synergy Prediction.Journal of chemical information and modeling · 2024
    Article
  4. Iranian journal of public health · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anna PryczyniczAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Mariusz GrykoAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Katarzyna NiewiarowskaAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Dariusz CepowiczAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Marek UstymowiczAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Andrzej KemonaAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Katarzyna Guzińska-UstymowiczAnna Pryczynicz, Katarzyna Niewiarowska, Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Department of General Pathomorphology, Medical University of Bialystok, 15-269 Bialystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the expression of Bcl-xL, Bak, and Bax proteins in correlation with particular clinico-histopathological parameters, including tumor invasion front, in patients with colorectal cancer.

methodsThe expression of these proteins was evaluated with the use of the immunohistochemical method in 50 primary tumors.

resultsAccording to observations, a low expression of Bax and Bak proteins is related to the localization of the tumor in the rectum (P < 0.05 and P < 0.05 respectively), which may explain an increased incidence of colorectal cancer in this area. A positive expression of Bax protein also correlates with the presence of cancer cell infiltration to lymph and blood vessels (P < 0.05), which may suggest the participation of this protein in the early stages of colorectal cancer progression. Moreover, a positive expression of Bcl-xL protein correlated with a positive expression of Bak protein. This may suggest a greater participation of Bcl-xL protein in the inhibition of the proapoptotic Bak protein, but not the Bax protein.

conclusionBax protein is probably very significant in the cancerogenesis mechanism in the large intestine.

Indexed as

bcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer Proteinbcl-X ProteinBiomarkers, TumorColorectal NeoplasmsDisease ProgressionFemaleHumansImmunohistochemistryMaleNeoplasm InvasivenessBAK1 protein, humanBAX protein, humanbcl-2-Associated X Proteinbcl-2 Homologous Antagonist-Killer ProteinBCL2L1 protein, humanbcl-X ProteinBiomarkers, TumorBakBaxBcl-xLCancer cell infiltrationColorectal cancer

Identifiers

PMID24574804
PMCPMC3921512
OpenAlexW1999154897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.